Arca
Skip to content
Tools
Tools

CDA: Cytidine deaminase

This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis. {ECO:0000269|PubMed:7923172, ECO:0000269|PubMed:9596658}.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on CDA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Cedazuridine

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        CedazuridineApprovedOtsuka Beijing Research InstituteSmall moleculeInhibitorCytidine deaminase inhibitor54

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AMLCedazuridinePhase 2Not yet recruitingRutgers, The State University of New JerseyOct 9, 2026
        Hydrochloroquinine & Decitabine With Venetoclax in AMLCedazuridinePhase 1Not yet recruitingRutgers, The State University of New JerseySep 10, 2026
        Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPNCedazuridinePhase 2RecruitingVirginia Commonwealth UniversityJul 17, 2026
        Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsCedazuridinePhase 2RecruitingPETHEMA FoundationApr 2, 2026
        ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1CedazuridinePhase 1 / Phase 2Not yet recruitingUniversity of Wisconsin, MadisonMar 16, 2026
        Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)CedazuridinePhase 2RecruitingNational Cancer Institute (NCI)Feb 27, 2026
        Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)CedazuridinePhase 2Not yet recruitingNational Cancer Institute (NCI)Sep 4, 2025
        Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsCedazuridinePhase 2RecruitingUniversity of WashingtonAug 29, 2025

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4502, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P32320, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.